Syneos Health, Inc., a fully integrated biopharmaceutical solutions organization, has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management, Patient Square Capital, and Veritas Capital, in a transaction valued at approximately $7.1 billion, including outstanding debt. The purchase price represents a 24% premium to Syneos Health’s unaffected closing stock price on February 13, 2023, the last trading da...